<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thrombin, topical (human, recombinant, and bovine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thrombin, topical (human, recombinant, and bovine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Thrombin, topical (human, recombinant, and bovine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11919" href="/d/html/11919.html" rel="external">see "Thrombin, topical (human, recombinant, and bovine): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12840" href="/d/html/12840.html" rel="external">see "Thrombin, topical (human, recombinant, and bovine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708964"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Severe bleeding and thrombosis complications: Thrombin topical (bovine) only: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thrombin topical (bovine) can cause fatal severe bleeding or thrombosis.  Thrombosis may result from the development of antibodies against bovine thrombin. Bleeding may result from the development of antibodies against factor V.  These may cross-react with human factor V and lead to its deficiency.  Do not re-expose patients to thrombin topical (bovine) if there are known or suspected antibodies to bovine thrombin and/or factor V.  Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F227307"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Floseal;</li>
<li>Floseal with Recothrom;</li>
<li>Recothrom;</li>
<li>Recothrom Spray Kit;</li>
<li>Thrombi-Gel;</li>
<li>Thrombi-Pad;</li>
<li>Thrombin-JMI;</li>
<li>Thrombin-JMI Epistaxis Kit;</li>
<li>Thrombin-JMI Pump Spray Kit;</li>
<li>Thrombin-JMI Syringe Spray Kit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914245"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Recothrom</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F227313"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        Hemostatic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F227309"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6a6a6e7-7f75-44b9-9e0d-8db24d457582">Hemostasis aid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemostasis aid:</b>
<b>Topical:</b>
<b>Note:</b> For topical use only; do not administer intravenously or intra-arterially:</p>
<p style="text-indent:-2em;margin-left:4em;">Recothrom: Dose depends on area to be treated. Apply to the bleeding site directly or in conjunction with absorbable gelatin sponge.</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Gel: Apply directly over source of the bleeding with adjunct manual pressure until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI:</p>
<p style="text-indent:-2em;margin-left:6em;">Solution: Apply 1,000 to 2,000 units/mL of solution where bleeding is profuse. Apply 100 units/mL for bleeding from skin or mucosal surfaces (eg, skin grafting, dental extractions, plastic surgery).</p>
<p style="text-indent:-2em;margin-left:6em;">Powder: May apply dry powder directly to the site on oozing surfaces.</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Pad: Apply dry or wetted pad directly over source of bleeding with adjunct manual pressure. If desired, product may be left in place for up to 24 hours; do not leave in the body.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990286"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987580"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F227310"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F5663803"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12840" href="/d/html/12840.html" rel="external">see "Thrombin, topical (human, recombinant, and bovine): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6a6a6e7-7f75-44b9-9e0d-8db24d457582">Hemostasis aid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemostasis aid:</b> Topical: <b>Note:</b> For topical use only; do not administer IV or intra-arterially:</p>
<p style="text-indent:-2em;margin-left:4em;">Recothrom: Infants, Children, and Adolescents: Dose depends on area to be treated including size of and number of bleeding sites; may apply directly or in conjunction with an absorbable gelatin sponge.</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI: Limited data available: <b>Note: </b>While reports in the literature have documented use in pediatric patients, they have focused on the development of coagulopathies due to inhibitor formation after bovine thrombin; few reports indicate dosing used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10498359','lexi-content-ref-17383385','lexi-content-ref-21228719','lexi-content-ref-16526049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10498359','lexi-content-ref-17383385','lexi-content-ref-21228719','lexi-content-ref-16526049'])">Ref</a></span>); dosing presented is reflective of manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Solution: Apply 1,000 to 2,000 units/mL of solution where bleeding is profuse. Apply 100 units/mL for bleeding from skin or mucosal surfaces (eg, skin grafting, dental extractions, plastic surgery).</p>
<p style="text-indent:-2em;margin-left:8em;">Powder: May apply dry powder directly to the site on oozing surfaces.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192737"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192738"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F227293"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≥2%), tachycardia (≥2%), thromboembolism (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≥2%), hemorrhage (≥2%; including major hemorrhage), thrombocytopenia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≥2% )</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased clotting factors (factor V), disseminated intravascular coagulation, postoperative hematoma, prolonged partial thromboplastin time, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Swelling</p></div>
<div class="block coi drugH1Div" id="F227303"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Recothrom: Additional contraindications: Known hypersensitivity to hamster proteins; injection directly into the circulatory system; treatment of massive or brisk arterial bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombi-Gel: Additional contraindications: Use in the closure of skin incisions.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombin-JMI: Additional contraindications: Known sensitivity to material of bovine origin; injection directly into the circulatory system; re-exposure if there are known or suspected antibodies to bovine thrombin and/or factor V; treatment of severe or brisk arterial bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombi-Pad: Additional contraindications: Known sensitivity to bovine-derived materials.</p></div>
<div class="block war drugH1Div" id="F227290"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, may occur. Institute supportive measure and treat individual symptoms immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunogenicity: Development of antibodies to thrombin topical (bovine) may occur and may interfere with hemostasis. Thrombosis may result from the development of antibodies against bovine thrombin. Bleeding may result from the development of antibodies against factor V. These may crossreact with human factor V and lead to its deficiency. Do not re-expose patients to thrombin topical (bovine) if there are known or suspected antibodies to bovine thrombin and/or factor V.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection risk: Thrombi-Gel and Thrombi-Pad: Do not use in the presence of infection; use caution in areas of contamination.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nonabsorbable product: Thrombi-Pad: Do not use as a replacement for absorbable hemostats. Product is nonabsorbable; do not leave in the body.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteins (snake and hamster origin): Recothrom: Use caution in patients with known hypersensitivity to snake or hamster proteins (manufacturing process uses a genetically modified hamster cell line and snake proteins); the potential for allergic reaction theoretically exists.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For topical use only. Do not inject intravenously or intra-arterially. Intravascular clotting, possibly leading to death, may occur following injection. Powder and solution formulations may be used in combination with absorbable gelatin sponges; the 5,000-unit syringe spray kit may be used in conjunction with Gel-Flow NT.</p></div>
<div class="block foc drugH1Div" id="F227299"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit for reconstitution, topical [human]:</p>
<p style="text-indent:-2em;margin-left:4em;">Floseal: 2,500 units, 5,000 units [supplied with diluent and gelatin matrix (bovine-derived)]</p>
<p style="text-indent:-2em;margin-left:2em;">Kit for reconstitution, topical [recombinant]:</p>
<p style="text-indent:-2em;margin-left:4em;">Floseal with Recothrom: 5,000 units [supplied with diluent and gelatin matrix (bovine-derived)]</p>
<p style="text-indent:-2em;margin-left:2em;">Pad, topical [preservative free; bovine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Pad 3x3: ≥200 units (10s)</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for reconstitution, topical [bovine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI: 5,000 units, 20,000 units [supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI Epistaxis kit: 5,000 units [supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI Pump Spray Kit: 20,000 units [supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombin-JMI Syringe Spray Kit: 5,000 units; 20,000 units [supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for reconstitution, topical [preservative free; recombinant]:</p>
<p style="text-indent:-2em;margin-left:4em;">Recothrom: 5,000 units, 20,000 units [production involves products derived from hamster and snake sources; supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:4em;">Recothrom Spray Kit: 20,000 units [production involves products derived from hamster and snake sources; supplied with diluent]</p>
<p style="text-indent:-2em;margin-left:2em;">Sponge, topical [preservative free; bovine derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Gel 10: ≥1,000 units (10s)</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Gel 40: ≥1,000 units (5s)</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Gel 100: ≥2,000 units (5s)</p></div>
<div class="block geq drugH1Div" id="F227286"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323961"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Thrombin-JMI Epistaxis External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 unit (per each): $101.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Thrombin-JMI External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 unit (per each): $96.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 unit (per each): $390.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Thrombogen External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $34.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pads</b> (Thrombi-Pad External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3"X3" (per each): $76.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Recothrom External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 unit (per each): $103.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 unit (per each): $412.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Recothrom Spray Kit External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 unit (per each): $418.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thrombin-JMI External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 unit (per each): $86.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 unit (per each): $341.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thrombogen External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (per each): $3.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $18.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F227301"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">For topical use only; do not administer intravenously or intra-arterially.</p>
<p style="text-indent:-2em;margin-left:2em;">Recothrom: May apply reconstituted solution directly using ZymoGenetics spray applicator kit or in combination with absorbable gelatin sponge. When using spray applicator, use the sterile bowl in kit as receptacle for reconstituted solution; refer to spray kit manufacturer’s labeling for spray pump and syringe spray assembly and use. When used in conjunction with absorbable gelatin sponge(s), transfer solution to sterile container and immerse gelatin sponge(s) into solution until completely saturated; gently squeeze to remove excess solution; apply sponge(s) to bleeding site in a single layer.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombi-Gel: After wetting, place directly over bleeding source and apply adjunct manual compression until hemostasis is achieved; may cut or roll to desired shape prior to wetting.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombin-JMI: Sponge (do not wipe) application surface prior to use, if possible. Apply as dry powder or reconstituted solution. When used as a solution, flood surface using a sterile syringe with a small-gauge needle or use in conjunction with Thrombin-JMI pump spray kit, syringe spray kit, or epistaxis kit; refer to manufacturer’s kit labeling for assembly and use. The 5,000 unit syringe spray kit may be used to saturate gelatin powder in Gel-Flow NT; mixture may be smeared, filled or pressed against surface to control bleeding (refer to Gel-Flow NT product labeling for preparation instructions). When used in conjunction with absorbable gelatin sponge, immerse sponge strips into solution; vigorously knead sponge with moistened gloved fingers until all air is expelled; apply saturated sponge to bleeding area; hold in place with gauze or cotton pledget using moderate pressure until hemostasis is achieved. Product is most effective when it mixes freely with blood as soon as it reaches the surface. Avoid sponging of treated surfaces.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombi-Pad: Apply dry or wet directly to the bleeding source and apply adjunct manual compression; may be left in place for up to 24 hours. To remove, do not disrupt clot by physical manipulation. If pad adheres to the site, irrigate with nonheparinized NS and remove.</p></div>
<div class="block admp drugH1Div" id="F52613924"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: For topical use only; do not administer IV or intra-arterially.</p>
<p style="text-indent:-2em;margin-left:2em;">Recothrom: May apply reconstituted solution directly using spray applicator kit or in combination with absorbable gelatin sponge.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Use with spray applicator</i>: Use the sterile bowl in kit as receptacle for reconstituted solution; refer to spray kit manufacturer's labeling for spray pump and syringe spray assembly and use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Use with gelatin sponge</i>: Transfer solution to sterile container and immerse gelatin sponge(s) into solution until completely saturated; gently squeeze to remove excess solution; apply sponge(s) to bleeding site in a single layer.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombin-JMI: May be applied directly as a powder or as reconstituted solution. Sponge (do not wipe) application surface prior to use, if possible. Product is most effective when it mixes freely with blood as soon as it reaches the surface. Avoid sponging of treated surfaces.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Use as topical solution</i>: Flood surface using a sterile syringe with a small-gauge needle or use in conjunction with Thrombin-JMI pump spray kit, syringe spray kit, or epistaxis kit; refer to manufacturer's kit labeling for assembly and use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Use with gelatin sponge:</i> Immerse sponge strips into reconstituted thrombin solution; vigorously knead sponge with moistened gloved fingers until all air is expelled; apply saturated sponge to bleeding area; hold in place with gauze or cotton pledget using moderate pressure until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Use with Gel-Flow NT:</i> The 5,000 unit syringe spray kit may be used to saturate gelatin powder in Gel-Flow NT; mixture may be smeared, filled, or pressed against surface to control bleeding; refer to Gel-Flow NT product labeling for preparation instructions.</p></div>
<div class="block use drugH1Div" id="F227300"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemostasis aid:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Recothrom, Thrombin-JMI only: As an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.</p>
<p style="text-indent:-2em;margin-left:4em;">Thrombi-Gel, Thrombi-Pad only: As a trauma dressing for temporary control of moderate to severe bleeding wounds; control of surface bleeding from vascular access sites and percutaneous catheters and tubes.</p></div>
<div class="block mst drugH1Div" id="F5663226"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Thrombin (topical) may be confused with antithrombin, Thrombate III</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">For topical use only. Do not administer intravenously or intra-arterially.</p>
<p style="text-indent:-2em;margin-left:4em;">To reduce the risk of intravascular administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:</p>
<p style="text-indent:-2em;margin-left:6em;">- Prepare, label, and dispense topical thrombin from the pharmacy department (including doses used in the operating room).</p>
<p style="text-indent:-2em;margin-left:6em;">- Do not leave vial or syringe at bedside.</p>
<p style="text-indent:-2em;margin-left:6em;">- Add auxiliary label to all labels and syringes stating “For topical use only - do not inject”.</p>
<p style="text-indent:-2em;margin-left:6em;">- When appropriate, use solutions which can be applied with an absorbable gelatin sponge or use a dry form on oozing surfaces.</p>
<p style="text-indent:-2em;margin-left:6em;">- When appropriate, use spray kits to help differentiate between parenteral products.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300134"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F227294"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5663227"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Data related to the use of topical hemostatic agents in gynecologic surgery are limited; routine prophylactic use for postoperative bleeding is not recommended due to the increased risk of infection and other complications (ACOG 2020).</p></div>
<div class="block brc drugH1Div" id="F20305851"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if thrombin topical is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F44472814"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Signs of hypersensitivity, bleeding, thrombosis, abnormal coagulation laboratory values.</p></div>
<div class="block pha drugH1Div" id="F227289"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">When applied to bleeding sites, activates platelets and catalyzes the conversion of fibrinogen to fibrin to promote hemostasis.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32976379">
<a name="32976379"></a>American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Topical hemostatic agents at time of obstetric and gynecologic surgery: ACOG committee opinion, number 812. <i>Obstet Gynecol</i>. 2020;136(4):e81-e89. doi:10.1097/AOG.0000000000004104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thrombin-topical-human-recombinant-and-bovine-drug-information/abstract-text/32976379/pubmed" id="32976379" target="_blank">32976379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10498359">
<a name="10498359"></a>Barret JP, Dziewulski P, Wolf SE, Desai MH, Nichols RJ 2nd, Herndon DN. Effect of topical and subcutaneous epinephrine in combination with topical thrombin in blood loss during immediate near-total burn wound excision in pediatric burned patients. <i>Burns</i>. 1999;25(6):509-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thrombin-topical-human-recombinant-and-bovine-drug-information/abstract-text/10498359/pubmed" id="10498359" target="_blank">10498359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17383385">
<a name="17383385"></a>Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. <i>Ann Thorac Surg</i>. 2007;83(4):1547-1549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thrombin-topical-human-recombinant-and-bovine-drug-information/abstract-text/17383385/pubmed" id="17383385" target="_blank">17383385</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gel-Flow NT (gelatin) [prescribing information]. New York, NY: Pfizer; July 2019.</div>
</li>
<li>
<div class="reference">
                  Recothrom (thrombin) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; December 2020.</div>
</li>
<li>
<div class="reference">
                  Recothrom (thrombin alfa) [product monograph]. Parsippany, NJ: The Medicines Company; February 7, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21228719">
<a name="21228719"></a>Rodgers GM. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature. <i>J Pediatr Hematol Oncol</i>. 2011;33(2):86-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thrombin-topical-human-recombinant-and-bovine-drug-information/abstract-text/21228719/pubmed" id="21228719" target="_blank">21228719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16526049">
<a name="16526049"></a>Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. <i>Pediatr Blood Cancer</i>. 2007;49(7):1025-1029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/thrombin-topical-human-recombinant-and-bovine-drug-information/abstract-text/16526049/pubmed" id="16526049" target="_blank">16526049</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Thrombi-Gel (thrombin) [prescribing information]. New York, NY: Pfizer Inc; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thrombin.1">
<a name="Thrombin.1"></a>Thrombin-JMI (thrombin) [prescribing information]. Middleton, WI: GenTrac Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Thrombin-JMI (thrombin) [prescribing information]. New York, NY: Pfizer Inc; March 2019.</div>
</li>
<li>
<div class="reference">
                  Thrombi-Pad (thrombin) [prescribing information]. New York, NY: Pfizer Inc; August 2014.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10285 Version 257.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
